KLOW Stack
GLOW blend plus KPV anti-inflammatory tripeptide
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The combination itself is essentially unstudied. There are no published human trials of KLOW, no pharmacokinetic work on the four peptides given together, and nothing that tests whether the additions are additive, redundant, or interfering. Every claim made for the stack is borrowed from evidence about single components, and most of that evidence is preclinical. KPV has the most coherent laboratory story of the four, with repeated demonstrations of reduced inflammatory signalling and improved outcomes in chemically induced mouse colitis models, plus cell-culture work on epithelial and immune cells. Those findings are consistent but they are in rodents and dishes, and oral or systemic KPV has not been shown to treat inflammatory bowel disease in people. GHK-Cu has genuine human data, though almost entirely topical and cosmetic, on skin appearance and collagen markers, usually in small studies. BPC-157 has an unusually large animal literature from a single research group and no completed, published, peer-reviewed randomised human trial demonstrating healing benefit. TB-500 has essentially no human efficacy evidence. Adding a fourth peptide multiplies the unknowns rather than strengthening the case.
- FDA
- No ingredient in KLOW is an FDA-approved drug. BPC-157 and TB-500 were placed on the FDA restricted compounding list in late 2023. KPV and GHK-Cu are not approved drugs either. Almost all product is sold as research-use-only, not for human use.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
Honest risk is high. No KLOW ingredient is an FDA-approved drug, two were restricted by the FDA, and the four-peptide blend has zero published human trials. Adding KPV increases the number of unstudied interactions, not the amount of human safety data. Product is sold research-use-only, so purity, sterility, and contents are unregulated and inconsistent. Injection carries infection and contamination risk. KPV affects immune signaling, and the long-term consequences of suppressing inflammation pathways with an unregulated product in people are unknown. Sourcing varies widely between vendors.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about KLOW Stack. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
KLOW is the GLOW blend with a fourth peptide, KPV, added. KPV is a tripeptide (a chain of three amino acids: lysine, proline, and valine) that comes from the tail end of alpha-MSH, a natural hormone that affects pigment and inflammation. KPV is studied for calming inflammation without the pigment effect of the full hormone. The idea behind KLOW is to combine skin and healing peptides (GHK-Cu, BPC-157, TB-500) with an anti-inflammatory one (KPV) for skin, gut, and inflammation goals. Like GLOW, it is usually injected and is legally sold as a research chemical rather than a medicine. There are no published human trials of this four-peptide combination, and the name comes from the online peptide community rather than any medical authority.
Skin, healing, and anti-inflammation blend
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
None of the four peptides is an approved medicine in the United States, the European Union, the United Kingdom, Australia, or Japan. BPC-157 and thymosin beta-4 were placed by the FDA in the category of bulk substances raising significant safety concerns for compounding, which removed the main quasi-legal supply route in the US. GHK-Cu is permitted in topical cosmetics in many markets, including under EU cosmetic rules, but that says nothing about injecting it. BPC-157 and thymosin beta-4 are prohibited at all times under the WADA list, so any athlete in a tested sport is at risk. KPV sits in a grey zone, unlisted rather than cleared. Because almost all supply is research-use-only, dose accuracy, sterility, endotoxin load, and actual peptide identity are unverified. What the combination does when all four are present at once has never been measured in a person.
What people get wrong
Often saidMyth: KLOW is a stronger, proven upgrade to GLOW.
ActuallyReality: Adding a fourth unapproved peptide multiplies unknown interactions, not human proof; the blend has no trials.
Often saidMyth: KPV is well tested in this combination.
ActuallyReality: KPV's anti-inflammatory data are preclinical (cells and animals); the four-peptide blend is untested in people.
Who profits, and who pushes back
US Food and Drug Administration
Restricted BPC-157 and TB-500 over safety, impurity, and missing human-data concerns; none of the KLOW peptides is approved.
Banned Substances Control Group (BSCG)
Flags TB-500 as banned with no established human safety profile.
Independent reviewers
Note KPV evidence is preclinical (cells and animals) and that stacking four unapproved peptides multiplies unknowns rather than adding proof.
Peptide vendors and compounding-style suppliers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Position KLOW as a premium upgrade to GLOW; direct sales interest.
Telehealth peptide clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Bundle KLOW into recurring programs; revenue tied to retention.
Aesthetic and gut-health influencers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Mix of disclosed affiliates and unpaid believers reporting personal anti-inflammatory results.
Jay Campbell and peptide-community publishers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Publish GLOW-versus-KLOW comparisons; commerce and belief overlap.
Where the research comes from
Most of the published research on this comes from one place. 58% of it is from United States. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| United States | 58% |
| Europe | 18% |
| Other | 13% |
| Australia and New Zealand | 11% |
Research published from: US.
How we got here
The name circulates entirely within online peptide forums, Telegram groups, and compounding-adjacent vendor catalogues, where it reads as GLOW with a K bolted onto the front for KPV. No clinic, company, or author is documented as having coined it, and the earliest uses are impossible to date reliably because the venues where it appeared are unarchived. Each component has a real and traceable origin, which is part of why the blend feels more credible than it is. GHK-Cu came out of Loren Pickart's work on plasma fractions at the University of California in the early 1970s. BPC-157 emerged from Predrag Sikiric's group in Zagreb, derived from a sequence in human gastric juice. Thymosin beta-4, from which TB-500 is drawn, traces to thymic peptide research at the US National Institutes of Health in the 1960s and 1970s. KPV is the terminal three residues of alpha-MSH, and its anti-inflammatory behaviour has been explored in laboratory models since at least the 1990s, with a body of mouse colitis work published in the 2000s and 2010s. What no lineage supports is the four together. The pairing was assembled by sellers and users, not by anyone who tested it.
KLOW is community-attributed, like GLOW; no individual or company is documented as having coined it, and the origin is uncertain. It is simply GLOW (GHK-Cu, BPC-157, TB-500) with KPV added. KPV is the fragment at positions 11 to 13 of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural hormone made in the pituitary gland; its anti-inflammatory behavior has been studied in laboratory and animal models for roughly two decades, especially for gut and skin inflammation. The other three peptides trace to Loren Pickart (GHK-Cu, 1973), Predrag Sikiric and the Zagreb group (BPC-157), and thymosin beta-4 research (TB-500). None of these original researchers is credited with creating KLOW; the four-peptide bundle is a vendor and community construction that has not been independently validated as a protocol.
- 1973GHK-Cu isolated from human plasma by Loren Pickart
- 1990s-2000sBPC-157 (Sikiric, Zagreb) and KPV anti-inflammatory research develop separately
- 2010sPeptides circulate as research chemicals in biohacker communities
- Early 2020sGLOW branded; KPV added by vendors to create KLOW
- 2022WADA lists BPC-157 and TB-500 as banned
- Late 2023FDA restricts BPC-157 and TB-500 for compounding
At a glance
- Components
- GHK-Cu, BPC-157, TB-500, KPV
- What KPV adds
- Anti-inflammatory signaling
- Human trials of the blend
- None published
- Regulatory status
- Not FDA-approved; mostly research-use-only
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about KLOW Stack. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
BPC-157 and thymosin beta-4 were placed by the FDA in the compounding category for substances raising significant safety concerns, restricting their use in compounded preparations.
BPC-157 and thymosin beta-4 are prohibited at all times in sport under the World Anti-Doping Code Prohibited List.
Athletes are warned that peptides sold as research chemicals, including BPC-157, carry sanction risk and unverified contents.
KPV, the C-terminal tripeptide of alpha-MSH, reduces inflammatory signalling and improves outcomes in rodent models of experimental colitis.
Peer-reviewed preclinical literature indexed in PubMed
GHK-Cu has been studied primarily as a topical cosmetic and wound-healing agent, with human data limited to small studies of skin appearance and collagen markers.
Peer-reviewed review literature indexed in PubMed
The large BPC-157 animal literature originates predominantly from one research group in Zagreb, and no completed published randomised human efficacy trial exists.
Peer-reviewed literature indexed in PubMed
No registered or completed clinical trial evaluates the four-peptide KLOW combination in humans.
Copper peptides including GHK-Cu are permitted in topical cosmetic products in the European Union, which does not imply any approval for injection.
European Commission cosmetic ingredient framework